✦ LIBER ✦

Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients with Connective Tissue Diseases

✍ Scribed by Passawee Vananuvat; Parawee Suwannalai; Somnuek Sungkanuparph; Ticha Limsuwan; Pintip Ngamjanyaporn; Suchela Janwityanujit

Book ID: 113900046
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 199 KB
Volume: 41
Category: Article
ISSN: 0049-0172
DOI: 10.1016/j.semarthrit.2011.05.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk Factors for Pneumocystis jirovecii

Risk Factors for Pneumocystis jirovecii Pneumonia in Patients With Lymphoproliferative Disorders

✍ Karam M. Obeid; Javier Aguilar; Susan Szpunar; Mamta Sharma; Ramon del Busto; Ay 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 228 KB

Pneumocystis carinii pneumonia prophylax

Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma

✍ Beela S Mathew; Stuart A Grossman 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 207 KB

Pneumocystis carinii pneumonia in patien

Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality

✍ Michael M. Ward; Fiona Donald 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

Development of Pneumocystis carinii pneu

Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications

✍ Jacqueline L. Gerhart; Amer N. Kalaaji 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 150 KB

High Prevalence of Dihydropteroate Synth

High Prevalence of Dihydropteroate Synthase Mutations in Pneumocystis jirovecii Isolated from Patients with Pneumocystis Pneumonia in South Africa

✍ Dini, L.; du Plessis, M.; Frean, J.; Fernandez, V. 📂 Article 📅 2010 🏛 American Society for Microbiology 🌐 English ⚖ 73 KB

Prophylaxis against Pneumocystis pneumon

Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: Toward a standard of care

✍ David M. Poppers; Ellen J. Scherl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

Patients with Crohn's Disease and ulcerative colitis are increasingly treated with a host of immunomodulatory and immunosuppressive medications, including thiopurines and antibody-based biologic agents. Despite the known infectious complications associated with these therapies from the HIV and solid